Therapy of chronic hepatitis C;Therapie der chronischen hepatitis C

Praxis

Volumn 95, Issue 38, 2006, Pages 1451-1457

  Moradpour, D ^a   Blum, H E ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Hepatits C virus; Pegylated interferon ; Ribavirin

Indexed keywords

EID: 80051664323     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157.95.38.1451     Document Type: Review

References (50)

1. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Hepatology 36 (Suppl 1): S2-S20, 2002.
2. Strader D.B., Wright T., Thomas D.L., Seeff L.B.: Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171, 2004. (Pubitemid 38428955)
3. Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M.: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331-338, 2003. (Pubitemid 36443043)
4. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362, 1989. (Pubitemid 19117877)
5. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P. et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973, 2005. (Pubitemid 41401136)
6. Lindenbach B.D., Rice C.M.: Unravelling hepatitis C virus replication from genome to function. Nature 436: 933-938, 2005. (Pubitemid 41191668)
7. Moradpour D., Rice C.M.: Replication and pathogenesis of hepatitis C virus. In: Boyer TD, Manns MP, Wright TL, eds. Hepatology. A textbook of liver disease. Philadelphia, PA: Elsevier Science, 5th ed., 2006, pp. 125-147.
8. Shepard C.W., Finelli L., Alter M.J.: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567, 2005. (Pubitemid 41196755)
9. Stramer S.L., Glynn S.A., Kleinman S.H., Strong D.M., Sally C., Wright D.J., Dodd R.Y. et al.: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 351: 760-768, 2004.
10. El-Serag H.B.: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-34, 2004.
11. Pessione F., Ramond M.J., Njapoum C., Duchatelle V., Degott C., Erlinger S., Rueff B. et al.: Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 34: 121-125, 2001. (Pubitemid 32591491)
12. Hezode C., Roudot-Thoraval F., Nguyen S., Grenard P., Julien B., Zafrani E.S., Pawlotsky J.M. et al.: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42: 63-71, 2005. (Pubitemid 40911312)
13. Fartoux L., Chazouilleres O., Wendum D., Poupon R., Serfaty L.: Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41: 82-87, 2005. (Pubitemid 40066385)
14. Gisbert J.P., Garcia-Buey L., Pajares J.M., Moreno-Otero R.: Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 125: 1723-1732, 2003. (Pubitemid 37500437)
15. Bedossa P., Dargere D., Paradis V.: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38: 1449-1457, 2003. (Pubitemid 37466971)
16. Colloredo G., Guido M., Sonzogni A., Leandro G.: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39: 239-244, 2003. (Pubitemid 36920560)
17. Bissell D.M.: Assessing fibrosis without liver biopsy: are we there yet? Gastroenterology 127: 1847-1849, 2004.
18. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., Darriet M. et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128: 343-350, 2005. (Pubitemid 40439195)
19. Ghany M.G., Doo E.: Assessment of liver fibrosis: palpate, poke or pulse? Hepatology 42: 759-761, 2005. (Pubitemid 41401112)
20. Jeffers L.J., Cassidy W., Howell C.D., Hu S., Reddy K.R.: Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708, 2004. (Pubitemid 38702672)
21. Muir A.J., Bornstein J.D., Killenberg PG.: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265-2271, 2004. (Pubitemid 38669209)
22. Bressler B.L., Guindi M., Tomlinson G., Heathcote J.: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639-644, 2003. (Pubitemid 37052150)
23. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., Corpas R. et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641, 2005. (Pubitemid 40585366)
24. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., Heathcote J. et al.: Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444, 2005. (Pubitemid 40712193)
25. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K. et al.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966, 2001. (Pubitemid 32240314)
26. Schaefer M., Schmidt F., Folwaczny C., Lorenz R., Martin G., Schindlbeck N., Heldwein W. et al.: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37: 443-451, 2003. (Pubitemid 36152544)
27. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., Wright T. et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126: 1302-1311, 2004. (Pubitemid 38552795)
28. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., Vinelli F. et al.: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005. (Pubitemid 41007847)
29. von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., Bergk A. et al.: Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522-527, 2005. (Pubitemid 41096640)
30. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., Ibranyi E. et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2005, 44: 97-103, 2006. (Pubitemid 41772522)
31. Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Goncales F.J., Häussinger D. et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
32. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B. et al.: Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609, 2003. (Pubitemid 36258782)
33. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D. et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001. (Pubitemid 32913521)
34. Hadziyannis S.J., Sette H. Jr., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G. et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
35. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., Morishima C., Wright E.C., Everson G.T., Lok A.S. et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126: 1015-1023; discussion 1947, 2004.
36. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G. et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1452-1457, 2001.
37. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., Schraut W.W. et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80-88, 2003. (Pubitemid 36799109)
38. Jacobson I.M., Ahmed F., Russo M.W., Lebovics E., Dieterich D.T., Esposito S.P., Bach N. et al.: Interferon alpha-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 99: 1700-1705, 2004. (Pubitemid 39237495)
39. Zeuzem S., Diago M., Gane E., Reddy K.R., Pockros P.J., Prati D., Shiffman M.L. et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724-1732, 2004. (Pubitemid 39575851)
40. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., Peters M.G. et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351: 451-459, 2004. (Pubitemid 38988594)
41. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., Carosi G. et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351: 438-450, 2004. (Pubitemid 38988593)
42. Brown R.S.: Hepatitis C and liver transplantation. Nature 436: 973-978, 2005.
43. Garcia-Retortillo M., Forns X.: Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 41: 2-10, 2004. (Pubitemid 39005145)
44. De Francesco R., Migliaccio G.: Challenges and successes in developing new therapies for hepatitis C. Nature 436: 953-960, 2005. (Pubitemid 41191671)
45. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M. et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426: 186-189, 2003. (Pubitemid 37442587)
46. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., Forns X. et al.: Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127: 1347-1355, 2004. (Pubitemid 39457761)
47. O'Brien C., Godofsky E., Rodriguez-Torres M., Afdhal N., Pockros P., Lawitz E., Bzowej N. et al.: Randomized trial of valopicitabine (NM283), alone or with PEG-interferon-alpha (PEG-IFN-alpha), vs. retreatment with PEG-IFN-alpha plus ribavirin (RBV) in hepatitis C patients with previous non-response to PEG-IFN-alpha/RBV: first interim results. Hepatology 42 (Suppl 1): 234A, 2005.
48. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., van de Wetering de Rooij J., McNair L.A. et al.: Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42 (Suppl 1): 234A, 2005.
49. Zeuzem S., Sarrazin C., Rouzier R., Tarral A., Brion N., Forestier N., Gupta S. et al.: Antiviral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype 1 patients refractory to pegylated interferon-alpha. Hepatology 42 (Suppl 1): 233A, 2005.
50. Houghton M., Abrignani S.: Prospects for a vaccine against the hepatitis C virus. Nature 436: 961-966, 2005. (Pubitemid 41191672)